US OptionsDetailed Quotes
ITOS250117C17000
- 0.05
- 0.000.00%
15min DelayClose Dec 23 16:00 ET
0.00High0.00Low
0.05Open0.05Pre Close0 Volume3 Open Interest17.00Strike Price0.00Turnover168.51%IV131.97%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.0443Delta0.0293Gamma147.00Leverage Ratio-0.0060Theta0.0002Rho6.51Eff Leverage0.0018Vega
ITeos Therapeutics Stock Discussion
iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress
Thursday, 12th December at 8:55 am
- Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS of 7.7 months for all evaluable patients across the cohorts
- Recommended Phase 2 dose (RP2D) of inupadenant 80mg + carboplatin/pemetrexed demonstrat...
$ITeos Therapeutics (ITOS.US)$
$Montrose Environmental (MEG.US)$
$Nurix Therapeutics (NRIX.US)$
$Pearson (PSO.US)$
$UnitedHealth (UNH.US)$
$Option Care Health (OPCH.US)$
$Procter & Gamble (PG.US)$
$Montrose Environmental (MEG.US)$
$Nurix Therapeutics (NRIX.US)$
$Datadog (DDOG.US)$
$Pearson (PSO.US)$
$Procter & Gamble (PG.US)$
$Option Care Health (OPCH.US)$
$UnitedHealth (UNH.US)$
No comment yet